Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares of Stock

Posted by Geri Gentry on Oct 1st, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at $75,855,438.40. The trade was a 4.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Nello Mainolfi also recently made the following trade(s):

On Tuesday, July 7th, Nello Mainolfi sold 50,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $119.00, for a total value of $5,950,000.00.

Kymera Therapeutics Trading Down 1.5%

NASDAQ:KYMR traded down $1.67 on Thursday, hitting $110.12. The company’s stock had a trading volume of 1,051,064 shares, compared to its average volume of 740,223. Kymera Therapeutics, Inc. has a one year low of $54.35 and a one year high of $130.05. The firm has a market capitalization of $9.16 billion, a P/E ratio of -33.99 and a beta of 1.96. The stock has a fifty day moving average of $114.69 and a two-hundred day moving average of $98.65.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. During the same period in the previous year, the company posted ($0.95) EPS. The firm’s revenue for the quarter was up 465.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.83 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. Merck & Co. Inc. acquired a new stake in shares of Kymera Therapeutics during the second quarter worth $88,544,161. Deutsche Bank AG acquired a new position in shares of Kymera Therapeutics in the second quarter valued at about $12,161,000. Eagle Health Investments LP acquired a new position in shares of Kymera Therapeutics in the second quarter valued at about $19,052,000. Legal & General Group Plc acquired a new position in shares of Kymera Therapeutics in the second quarter valued at about $4,155,000. Finally, BlackRock Inc. bought a new position in Kymera Therapeutics during the second quarter worth about $635,067,000.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. Royal Bank Of Canada downgraded shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their target price for the stock from $106.00 to $115.00 in a report on Monday, July 13th. Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 price target on the stock in a research note on Thursday, September 10th. Mizuho increased their price target on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Finally, B. Riley Financial raised their price objective on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $133.21.

Get Our Latest Report on Kymera Therapeutics

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively remove disease-causing proteins from cells. The company uses its targeted protein degradation platform, including molecular glue degraders, to address proteins that may be difficult to inhibit with conventional small-molecule drugs.

Kymera’s research and development activities center on immune-inflammatory diseases and cancer. Its pipeline has included investigational degraders designed to target proteins such as interleukin-1 receptor-associated kinase 4 (IRAK4) and signal transducer and activator of transcription 6 (STAT6), with the goal of treating conditions involving abnormal immune signaling.